Trilaciclib to prevent low blood cell counts in head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called trilaciclib to see if it can protect your blood cell counts during treatment for head and neck cancer that has come back or spread. You must not have had chemotherapy before for this stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has come back or spread, and you haven't had chemotherapy or other systemic therapy for this stage yet.
- You are at least 18 years old.
- You have at least one tumor that can be measured on scans.
- You are in good overall health (ECOG performance status 0 or 1) and expected to live at least 3 months.
- Your blood counts and kidney/liver function are within certain limits (hemoglobin, neutrophils, platelets, creatinine, bilirubin, liver enzymes, and albumin).
- Women who could become pregnant must have a negative pregnancy test and use reliable contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.